| 1 |
Family history of FXTAS is associated with age-related cognitive-linguistic decline among mothers with the FMR1 premutation.
|
|
|
|
In: Journal of neurodevelopmental disorders, vol 14, iss 1 (2022)
|
|
BASE
|
|
Show details
|
|
|
| 2 |
Providing a parent-administered outcome measure in a bilingual family of a father and a mother of two adolescents with ASD: brief report.
|
|
|
|
In: Developmental neurorehabilitation, vol 25, iss 2 (2022)
|
|
BASE
|
|
Show details
|
|
|
| 3 |
Providing a parent-administered outcome measure in a bilingual family of a father and a mother of two adolescents with ASD: brief report.
|
|
|
|
BASE
|
|
Show details
|
|
|
| 4 |
Pre-treatment clinical and gene expression patterns predict developmental change in early intervention in autism.
|
|
|
|
In: Molecular psychiatry, vol 26, iss 12 (2021)
|
|
BASE
|
|
Show details
|
|
|
| 5 |
Concurrent Associations between Expressive Language Ability and Independence in Adolescents and Adults with Fragile X Syndrome.
|
|
|
|
In: Brain sciences, vol 11, iss 9 (2021)
|
|
BASE
|
|
Show details
|
|
|
| 6 |
Concurrent Associations between Expressive Language Ability and Independence in Adolescents and Adults with Fragile X Syndrome.
|
|
|
|
In: Brain sciences, vol 11, iss 9 (2021)
|
|
BASE
|
|
Show details
|
|
|
| 7 |
Expressive language development in adolescents with Down syndrome and fragile X syndrome: change over time and the role of family-related factors.
|
|
|
|
In: Journal of neurodevelopmental disorders, vol 12, iss 1 (2020)
|
|
BASE
|
|
Show details
|
|
|
| 8 |
A neurophysiological model of speech production deficits in fragile X syndrome.
|
|
|
|
In: Brain communications, vol 2, iss 1 (2020)
|
|
BASE
|
|
Show details
|
|
|
| 9 |
Screen time in 36-month-olds at increased likelihood for ASD and ADHD.
|
|
|
|
BASE
|
|
Show details
|
|
|
| 10 |
Screen time in 36-month-olds at increased likelihood for ASD and ADHD.
|
|
|
|
BASE
|
|
Show details
|
|
|
| 11 |
Molecular Biomarkers Predictive of Sertraline Treatment Response in Young Children With Autism Spectrum Disorder.
|
|
|
|
Abstract:
Sertraline is one among several selective serotonin reuptake inhibitors (SSRIs) that exhibited improvement of language development in Autism Spectrum Disorder (ASD); however, the molecular mechanism has not been elucidated. A double blind, randomized, 6-month, placebo-controlled, clinical trial of low-dose sertraline in children ages (3-6 years) with ASD was conducted at the UC Davis MIND Institute. It aimed at evaluating the efficacy and benefit with respect to early expressive language development and global clinical improvement. This study aimed to identify molecular biomarkers that might be key players in the serotonin pathway and might be predictive of a clinical response to sertraline. Fifty eight subjects with the diagnosis of ASD were randomized to sertraline or placebo. Eight subjects from the sertraline arm and five from the placebo arm discontinued from the study. Furthermore, four subjects did not have a successful blood draw. Hence, genotypes for 41 subjects (20 on placebo and 21 on sertraline) were determined for several genes involved in the serotonin pathway including the serotonin transporter-linked polymorphic region (5-HTTLPR), the tryptophan hydroxylase 2 (TPH2), and the Brain-Derived Neurotrophic Factor (BDNF). In addition, plasma levels of BDNF, Matrix metallopeptidase 9 (MMP-9) and a selected panel of cytokines were determined at baseline and post-treatment. Intent-to-treat analysis revealed several primary significant correlations between molecular changes and the Mullen Scales of Early Learning (MSEL) and Clinical Global Impression Scale - Improvement (CGI-I) of treatment and control groups but they were not significant after adjustment for multiple testing. Thus, sertraline showed no benefit for treatment of young children with ASD in language development or changes in molecular markers in this study. These results indicate that sertraline may not be beneficial for the treatment of children with ASD; however, further investigation of larger groups as well as longer term follow-up studies are warranted.
|
|
Keyword:
6.1 Pharmaceuticals; Autism; Autism Spectrum Disorders; Brain Disorders; Clinical Research; Clinical Sciences; Clinical Trials and Supportive Activities; Genetics; Intellectual and Developmental Disabilities (IDD); Law; Mental Health; molecular biomarkers; Neurosciences; Pediatric; Prevention; selective serotonin reuptake inhibitor; serotonin; sertraline
|
|
URL: https://escholarship.org/uc/item/3n6774pz
|
|
BASE
|
|
Hide details
|
|
|
| 12 |
The Relationship between Expressive Language Sampling and Clinical Measures in Fragile X Syndrome and Typical Development.
|
|
|
|
In: Brain sciences, vol 10, iss 2 (2020)
|
|
BASE
|
|
Show details
|
|
|
| 13 |
Metformin treatment in young children with fragile X syndrome.
|
|
|
|
In: Molecular genetics & genomic medicine, vol 7, iss 11 (2019)
|
|
BASE
|
|
Show details
|
|
|
| 14 |
A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder.
|
|
|
|
BASE
|
|
Show details
|
|
|
| 15 |
Pathogenic variants in USP7 cause a neurodevelopmental disorder with speech delays, altered behavior, and neurologic anomalies.
|
|
|
|
In: Genetics in medicine : official journal of the American College of Medical Genetics, vol 21, iss 8 (2019)
|
|
BASE
|
|
Show details
|
|
|
| 16 |
A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder.
|
|
|
|
BASE
|
|
Show details
|
|
|
| 17 |
Large-scale associations between the leukocyte transcriptome and BOLD responses to speech differ in autism early language outcome subtypes.
|
|
|
|
In: Nature neuroscience, vol 21, iss 12 (2018)
|
|
BASE
|
|
Show details
|
|
|
| 18 |
Large-scale associations between the leukocyte transcriptome and BOLD responses to speech differ in autism early language outcome subtypes.
|
|
|
|
In: Nature neuroscience, vol 21, iss 12 (2018)
|
|
BASE
|
|
Show details
|
|
|
| 19 |
Magnetoencephalographic Imaging of Auditory and Somatosensory Cortical Responses in Children with Autism and Sensory Processing Dysfunction.
|
|
|
|
BASE
|
|
Show details
|
|
|
| 20 |
Investigation of autistic traits through strategic decision-making in games with adaptive agents.
|
|
|
|
In: Scientific reports, vol 7, iss 1 (2017)
|
|
BASE
|
|
Show details
|
|
|
|
|
